Cell assaying for pharma – prospects for technologies shaping that medical testing Visiongain’s new report, Cell-Based Assays World Industry and Market Prospects 2016-2026: Products, Services, Drug Discovery, ADME and Basic Research, examines those companies, trends, products, services and technologies. It investigates how those forces will shape that bioassays industry over the next ten years. To support that analysis with data, our study shows revenue forecasts at overall world, submarket and national level. Its purpose is to help companies and other organisations understand the potential of that cellular testing for medicine.
Use of cell lines in bioassays becomes more important in drug discovery and development. The cost of developing a new drug is now estimated to be around $2.6bn. Set against that background of rising costs, cell-based assays have become a vital tool for drug discovery, development and basic research. Those assays provide many advantages over traditional biochemical assays and animal models, and are continuing to improve owing to advances in high-throughput screening (HTS) technology, automation and miniaturisation. Cell-based assays can provide a more-accurate representation of human in vivo conditions; they are reliable and, most important for drug development companies, they have high efficiency.
Increasing prominence of technologies such as microfluidics, label-free systems, 3D cell-based assays and IPSC cell lines will stimulate revenue growth in the cellular testing market from 2015. As with any other market, it holds challenges. These include high initial set-up costs, high complexity, need for skilled staff to run and analyse tests, and long developmental times for new products. However, Visiongain predicts the cell-based assays market will grow strongly from 2016 to 2026, presenting many opportunities for assay product developers and suppliers, large CROs and specialist service providers, as well as many benefits for pharmaceutical companies.
Our work segments that bioassaying industry and market into two broad categories, with revenue forecasts to 2026 and discussions: • Products • Services
We also divide that medical testing industry into three main applications, again with sales forecasting: • Drug discovery uses • ADME (absorption, distribution, metabolism, excretion) testing • Basic research purposes
Besides forecasting revenues for the previous submarkets, our study also breaks its overall world market prediction into these 11 leading national markets, to 2026: • United States (US) • Japan • Germany, United Kingdom (UK), France, Spain, Italy (EU5 countries) • Brazil, Russia, India, China (BRIC nations)
And here lie technologies and trends we cover, among others, showing how they shape that worldwide market to 2026: • Stem cells (including IPSCs) for bioassays • 3D cell-based systems • Cell-based assaying for toxicity testing • Increased outsourcing for that cellular screening • Label-free technology • GPCRs (G-protein-coupled receptors) • Miniaturisation and automation • Microfluidics and multiplexing • High-content screening (HCS) • Cell lines for pharma in vitro assays • Cellular tests for the development of biologics (biological drugs)
Our 185page report provides 48 tables and 66 figures covering different market segments categorized by application: drug discovery, ADME, and basic research; as well as by sector: products and services.
Moreover, 11 individual national markets are covered in addition to 20 leading companies which sell products and provide services.
Cell-Based Assays World Industry and Market Prospects 2016-2026: Products, Services, Drug Discovery, ADME and Basic Research, published in May 2016, adds to Visiongain’s range of reports on industries and markets in healthcare. Its portfolio includes studies on pharmaceuticals, medical devices, diagnostic tests and outsourced services, including contract researchers, manufacturers and sellers.
Ways Cell-Based Assays World Industry and Market Prospects 2016-2026: Products, Services, Drug Discovery, ADME and Basic Research helps: In particular, our new investigation gives you this knowledge to benefit your research, analyses and planning: • Revenues for cellular assays, to 2026, at world level and for five submarkets – explore the prospects for design, production, sales, marketing, demand and spending • Forecasts, to 2026, for 11 countries in the Americas, Europe and Asia – assess the developed and developing national markets for demand and predicted revenues • Prospects for established firms, rising companies and new entrants – examine the product and service portfolios, results, strategies and outlooks for success • Analyses of what stimulates and restrains that industry’s participants – investigate the challenges, strengths and competition affecting organisations’ actions • Interviews with authorities in that field – discover what participants from the industry think, say and do, helping you stay ahead in business knowledge.
Information found nowhere else, benefiting your insight, work and influence Our study, produced in-house by our UK-based analysts, provides independent knowledge. You will gain competitive intelligence found only in our report, finding where the progress and business prospects exist.
With our definitive market data you’re less likely to fall behind in information or miss an opportunity. See how you could save time and effort. And, through your choice, benefit your plans, decisions and authority, helping you gain competitive advantages.
Data to help your knowledge of pharma R&D – benefit from our study now Our new analysis is for everyone investigating pharmaceutical research and development. For cellular assaying systems, you can explore the trends, results and revenue forecasts. So avoid missing out – please get that report here now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Cell-Based Assays Overview 1.2 Cell-Based Assays Market Segmentation 1.3 Why You Should Read This Report 1.4 How This Report Delivers 1.5 Questions Answered by this Report 1.6 Who is this Report for? 1.7 Research Methods and Analysis 1.8 Frequently Asked Questions 1.9 Associated Reports 1.10 About Visiongain
2. Introduction to Cell-Based Assays and Applications 2.1 Cost of New Drug Discovery and Development Reaches $2.6bn – Companies Constantly Looking for Increased Efficiencies 2.2 Drug Discovery Approaches – Target-Based and Phenotype-Based Discovery 2.3 Drug Screening Assays 2.4 Animal Models Present In Vivo Conditions: But Do Results Translate to Humans? 2.5 Biochemical Assays and their Advantages over Animal Models 2.5.1 Applications of Biochemical Assays 2.5.2 Lead Identification and Toxicity Testing 2.6 Cell-Based Assays and their Advantages 2.7 2D vs 3D Cell-Based Assays 2.8 Advanced Cell-Based Assays 2.9 The Different Assay Detection Methods and Technologies 2.10 Cells used in Cell-Based Assays 2.10.1 Immortalised Cell Lines – Convenient but not Truly Representative of Normal Human Cell Lines 2.10.2 Primary Cells: Closer to the In Vivo Environment 2.10.3 Stem Cells: Potential to Overcome Limitations of Primary cells and Immortalised Cell Lines 2.11 Uses for Cell-Based Assays in Drug Discovery and Development 2.11.1 Target Validation 2.11.2 Primary Screening 2.11.3 Secondary Screening 2.11.4 ADME Screening 2.11.5 High Throughput Screening: Greatly Increases Efficiency
3. World Cell-Based Assays Market 2016-2026 3.1 Global Cell-Based Assays Market Forecast 2016-2026 3.2 Drivers for the Cell-Based Assays Market 3.3 Restraints for the Cell-Based Assays Market 3.4 Cell-Based Assays: Market Segments – Products and Services 3.5 Cell-Based Assays, Market Segments: Products Forecast 2016-2026 3.5.1 The Four Main Categories of Cell-Based Assay Products 3.5.1.1 Equipment Needed to Conduct Cell-Based Assays 3.5.1.2 Disposables Necessary to Perform Cell-Based Assays 3.5.1.3 Consumables Forming the Basis of Cell-Based Assays 3.5.1.4 Biobanks 3.6 Cell-Based Assays Market Segments: Services 3.6.1 Cell-Based Assays Market Segments: Services Forecast 2016-2026 3.7 Cell-Based Assays Market: Applications Forecasts 2016-2026 3.7.1 Drug Discovery Segment 3.7.2 ADME (Absorption, Distribution, Metabolism, Excretion) Segment 3.7.3 Basic Research Segment
4. Leading National Markets for Cell-Based Assays, 2016-2026 4.1 Regional Breakdown of the Global Cell-Based Assays Market, 2016-2026 4.2 Global Cell-Based Assays market: Regional Forecast 2016-2026 4.3 The US Cell-Based Assays Revenue Forecast 2016-2026 4.4 European Union (EU) Cell-Based Assays Market 2016-2026 4.4.1 IMI’s Pan-European Drug Discovery Platform holds Much Promise 4.4.2 EU National Market Share Breakdown, 2015, 2020 and 2026 4.4.3 EU Market: Main National Forecasts, 2016-2026 4.4.4 German Cell-Based Assay Revenue Forecast, 2016-2026 4.4.5 French Cell-Based Assays Revenue Forecast, 2016-2026 4.4.6 UK Cell-Based Assays Revenue Forecast, 2016-2026 4.4.7 Spanish Cell-Based Assays Revenue Forecast, 2016-2026 4.4.8 Italian Cell-Based Assays Revenue Forecast, 2016-2026 4.5 Japanese Cell-Based Assays Revenue Forecast, 2016-2026 4.6 BRIC Nations (Brazil, Russia, India and China) Cell-Based Assays Market 4.6.1 BRIC Countries National Breakdown, 2015, 2020 and 2026 4.6.2 BRIC Countries National Forecasts, 2016-2026 4.6.3 Chinese Cell-Based assay Revenue Forecast, 2016-2026 4.6.4 Indian Cell-Based Assays Revenue Forecast, 2016-2026 4.6.5 Russian Cell-Based Assays Revenue Forecast, 2016-2026 4.6.6 Brazilian Cell-Based Assays Revenue Forecast, 2016-2026
5. Leading Companies in the Cell-Based Assays Market: Product Suppliers, 2016 5.1 Thermo Fisher Scientific 5.1.1 ThermoFisher Scientific Financial Figures 5.1.2 Recent Developments at ThermoFisher Scientific 5.1.2.1 ThermoFisher Acquires Affymetrix 5.1.3 Cell-Based Assay Technologies under ThermoFisher’s Life Science Solutions Segment 5.2 DiscoveRx 5.2.1 DiscoveRx Assay Platforms and Technology 5.3 PerkinElmer 5.3.1 AlphaScreen Technology 5.3.2 DELFIA TRF Assays 5.3.3 Label-Free Cellular Assay Detection/Opera System 5.4 BD (Becton, Dickinson and Company) 5.4.1 Cell-Based Assays Through BD Life Sciences 5.5 InSphero 5.5.1 GravityPLUS – Leading Solution for 3D Cell-Based Assays 5.6 QGel 5.6.1 QGel Products and Services 5.7 Biocroi 5.7.1 Happy Cell ASM and its 3D Cell Culture 5.8 GE Healthcare 5.8.1 Cell-Based Assays Through GE Healthcare Life Sciences 5.9 Molecular Devices 5.9.1 Cell-Based Assay Products Include SpectraMax Microplate Readers and FLIPR Tetra System 5.10 Promega 5.10.1 Assays Range from Cell Viability Assays to Mitochondrial Function Assays 5.11 BioVision 5.11.1 Cell-Based Assays Include the EZCell Platform and a Cholesterol Detection Kit
6. Leading Companies in the Cell-Based Assays Market: CROs and Service Providers, 2016 6.1 Porsolt: Acquires Fluofarma 6.1.1 Fluofarma 6.1.2 Fluofarma has Over 100 Cell-Based Assays 6.2 CYTOO 6.2.1 Cell Micropatterning to Eliminate Trade-off Between Quantity and Quality? 6.2.2 Cell-Based Assays for Muscular Atrophy/Hypertrophy and Anti-Cancer Drug Profiling 6.3 Cell Assay Innovations (CAI) 6.3.1 ClariCELL Technology 6.4 ProQinase 6.4.1 ProQinase Cell-Based Assay Services, 2016 6.5 Charles River Laboratories 6.5.1 PhenoFocus – Portfolio of over 100 Primary Cell-Based Assays 6.6 BioAgilytix 6.7 SGS 6.7.1 Offers a Range of Services, Including 3D Cell-Based Assays 6.8 Pharmaceutical Product Development 6.9 Marin Biologic Laboratories
7. Cell-Based Assays Technology, Trends and Future Outlook 7.1 Stem Cells: Vast Potential 7.1.1 The Benefits of Using Stem Cells in Cell-Based Assays 7.1.2 iPSCs: An Uncontroversial and Abundant Source 7.1.3 Companies Providing Stem Cell-Based Assays 7.2 Toxicity Testing: Important Field for Cell-Based Assays 7.3 3D Systems: The Advantages of Next Generation of Cell Systems 7.3.1 Complexity of 3D Systems is a Challenge but More are Reaching the Market 7.3.2 Organoids – The Future of Drug Development? 7.3.2.1 Hurdles to the Future Organoid Market 7.3.2.2 Organoids Now and in the Future 7.3.3 Bio-Printing for Drug Development: Using 3D Printing Technology 7.4 Increasing Outsourcing of Cell-Based Assays 7.5 Label-Free Technology 7.6 GPCRs: A Common Drug and Drug Discovery Target 7.6.1 GPCRs in Cell-Based Assays 7.6.2 Allosteric GPCRs 7.7 Increasing Miniaturisation and Automation 7.7.1 Advantages of Miniaturisation 7.7.2 Advantages of Automation 7.8 Microfluids are Set to be a Trend 7.8.1 The Potential Challenges to Microfluids 7.9 Multiplexing: Improves Efficiency of cell-Based Assays 7.9.1 Advantages will Drive Growth 7.10 High Content Screening: A Well Established Tool 7.10.1 The Future for HCS: Will Continue to Expand, Still Room for Innovation 7.11 Cell-Based Assays for the Development of Biologics
8. Qualitative Analysis of the Cell-Based Assays Market, 2016 8.1 SWOT Analysis of the Cell-Based Assays Market 8.1.1 Strengths Within the Cell-Based Assay Market 8.1.2 Weaknesses Within the Cell-Based Assays Market 8.1.3 Opportunities for the Cell-Based Assays Market 8.1.4 Threats to the Cell-Based Assays Market 8.2 STEP Analysis of the Cell-Based Assays Market 8.2.1 Social Factors 8.2.2 Technological Factors 8.2.3 Economic Factors 8.2.4 Political Factors
9. Research Interviews 9.1 Interview with Dr Colin Sanctuary, CEO of QGel 9.1.1 On the Definition of Cell-Based Assays 9.1.2 On QGel Company Background and QGel Offerings 9.1.3 On the Cell-Based Assay Market Now and in the Future 9.1.4 On the Challenges to Cell-Based Assays and the Cell-Based Assay Market 9.1.5 On Considerations to Take when Purchasing Cell-Based Assays
10. Conclusions from the Research and Analysis 10.1 Growth Has Been Driven by Advantages of Cell-Based Assays 10.2 Current Status of the Market and its Growth Drivers 10.3 The Most Dominant National Markets and Emerging Countries 10.4 Future Trends and Technology
Associated Reports Visiongain Report Sales Order Form About Visiongain Report Evaluation Form
List of Tables Table 1.1 Global Cell-Based Assays Market Regional Forecasts: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2026 Table 2.1 Main Parameters Required in Drug Discovery and Development Table 2.2 Selected Label-Free Detection Technologies Used for Cell-Based Assays, 2016 Table 2.3 Cell-Based Assays for HTS in Drug Screening, 2016 Table 3.1 Global Cell-Based Assays Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2026 Table 3.2 Global Cell-Based Assays Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2026 Table 3.3 Cell-Based Assays Market Segments: Products Forecast - Revenue ($m), AGR (%), CAGR (%), Market Share (%), 2016-2026 Table 3.4 Cell-Based Assays Market Segments: Services Forecast- Revenue ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026 Table 3.5 Cell-Based Assays Market Application Forecasts: Revenue ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026 Table 3.6 Drug Discovery Segment Forecast: Revenue ($m), AGR (%), CAGR (%), Market Share (%), 2016-2026 Table 3.7 ADME Segment Forecast: Revenue ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026 Table 3.8 Basic Research Segment Forecast: Revenue ($m), Market Share (%), AGR (%), CAGR (%), 2016-2026 Table 4.1 Cell-Based Assays Market Breakdown by Region: Revenues ($m), Market Shares (%), 2015 Table 4.2 Cell-Based Assays Market Breakdown by Region: Revenues ($m), Market Shares (%), 2020 Table 4.3 Cell-Based Assays Market Breakdown by Region: Revenues ($m), Market Shares (%), 2026 Table 4.4 Global Cell-Based Assays Market Regional Forecasts: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2026 Table 4.5 US Cell-Based Assays Market Forecast: Revenues ($m), AGR (%),Market Shares (%), CAGR (%), 2016-2026 Table 4.6 EU Cell-Based Assays Market Forecast: Revenues ($m), AGR (%), World Market Shares (%), CAGR (%), 2016-2026 Table 4.7 EU Market Breakdown by Leading Nation: EU Market Shares (%), Global Market Shares (%) and Revenues ($m), 2015 Table 4.8 EU Market Breakdown by Leading Nation: EU Market Shares (%), Global Market Shares (%) and Revenues ($m), 2020 Table 4.9 EU Market Breakdown by Leading Nation: EU Market Shares (%), Global Market Shares (%) and Revenues ($m), 2026 Table 4.10 EU Market, Leading Five National Forecasts: Revenue ($m), AGR (%),Market Share (%), CAGR (%), 2016-2026 Table 4.11 German Cell-Based Assays Market Forecast: Revenues ($m), AGR (%), Market Share (%), CAGR (%), 2016-2026 Table 4.12 French Cell-Based Assays Market Forecast: Revenues ($m), AGR (%), Market Share (%), CAGR (%), 2016-2026 Table 4.13 UK Cell-Based Assays Market Forecast: Revenues ($m), AGR (%), Market Share (%), CAGR (%), 2016-2026 Table 4.14 Spanish Cell-Based Assays Market Forecast: Revenues ($m), 2016-2026 Table 4.15 Italian Cell-Based Assays Market Forecast: Revenues ($m), 2016-2026 Table 4.16 Japanese Cell-Based Assays Market Forecast: Revenues ($m), 2016-2026 Table 4.17 BRIC Countries Breakdown by Nation: BRIC market Shares (%), Global Market Shares (%) and Revenues ($m), 2015 Table 4.18 BRIC Countries Breakdown by Nation: EU market Shares (%), Global Market Shares (%) and Revenues ($m), 2020 Table 4.19 BRIC Countries Breakdown by Nation: EU market Shares (%), Global Market Shares (%) and Revenues ($m), 2026 Table 4.20 BRIC National Forecasts: Revenue ($m), AGR (%), Market Share (%), CAGR (%), 2016-2026 Table 4.21 Chinese National Forecasts: Revenue ($m), AGR (%), Market Share (%), CAGR (%), 2016-2026 Table 4.22 Indian National Forecasts: Revenue ($m), AGR (%), Market Share (%), CAGR (%), 2016-2026 Table 4.23 Russian National Forecasts: Revenue ($m), AGR (%), Market Share (%), CAGR (%), 2016-2026 Table 4.24 Brazilian National Forecasts: Revenue ($m), AGR (%), Market Share (%), CAGR (%), 2016-2026 Table 5.1 ThermoFisher Scientific Historical Sales: Revenue ($m), AGR (%), 2010-2015 Table 5.2 Life Technologies Cell-Based Assay Technology Overview, 2016 Table 5.3 Life Technologies Cell-Based Assay Technology Overview, 2016 Table 5.4 Other DiscoveRx Assay Platforms, 2016 Table 5.5 PerkinElmer Revenue Breakdown: Revenue ($m) for Fiscal Year Ending 3rd January 2016 Table 5.6 QGel Products and Services Cell-Based Assay Products, 2016 Table 5.7 GE Healthcare Life Sciences Cell-Based Assay Products, 2016 Table 6.1 ProQinase Cell-Based Assay Services, 2016 Table 6.2 Charles River Laboratories Revenue Breakdown: Revenue ($m), 2013-2015 Table 6.3 Cell-Based Assay Platforms, Details and Benefits Used by BioAgilytix , 2016 Table 7.1 Selected Companies with Involvement in Stem Cell-Based Assays, 2016 Table 7.2 Selected Companies Offering Label-Free Assay Systems, 2016
List of Figures Figure 1.1 Cell-Based Assays Market Segmented by Application Figure 1.2 Cell-Based Assays Market Segmented by Sector Figure 1.3 Cell-Based Assays Products Market Segments Figure 2.1 Stages of Pre-Clinical Drug Development Figure 3.1 Global Cell-Based Assays Market Forecast: Revenue ($m), 2016-2026 Figure 3.2 Drivers and Restraints for the Cell-Based Assays Market, 2016 Figure 3.3 Cell-Based Assays Market Segments Forecasts: Revenue ($m), 2016-2026 Figure 3.4 Cell-Based Assays Market Segments: Products Forecast - Revenue ($m), 2016-2026 Figure 3.5 Cell-Based Assays Market Segments: Products Forecast - AGR (%), 2016-2026 Figure 3.6 Cell-Based Assay Products Overview, 2016 Figure 3.7 Cell-Based Assays Market Segments: Services Forecast - Revenue ($m), 2016-2026 Figure 3.8 Cell-Based Assays Market Segments: Services Forecast – AGR (%), 2016-2026 Figure 3.9 Cell-Based Assays Market Application Forecasts: Revenue ($m), 2016-2026 Figure 3.10 Drug Discovery Segment Forecast: Revenue ($m), 2016-2026 Figure 3.11 Drug Discovery Segment Forecast: AGR (%), 2016-2026 Figure 3.12 ADME Segment Forecast: Revenue ($m), 2016-2026 Figure 3.13 ADME Segment Forecast: AGR (%), 2016-2026 Figure 3.14 Basic Research Segment Forecast: Revenue ($m), 2016-2026 Figure 3.15 Basic Research Segment Forecast: AGR (%), 2016-2026 Figure 4.1 Cell-Based Assays Market Breakdown by Region: Revenues ($m), Market Shares (%), 2015 Figure 4.2 Cell-Based Assays Market Breakdown by Region: Revenues ($m), Market Shares (%), 2020 Figure 4.3 Cell-Based Assays Market Breakdown by Region: Revenues ($m), Market Shares (%), 2026 Figure 4.4 Global Cell-Based Assays Market, Regional Forecasts: Revenues ($m), 2016-2026 Figure 4.5 US Cell-Based Assays Market Forecast: Revenues ($m), 2016-2026 Figure 4.6 US Cell-Based Assays Market Forecast: AGR (%), 2016-2026 Figure 4.7 EU Cell-Based Assays Market Forecast: Revenues ($m), 2016-2026 Figure 4.8 EU Cell-Based Assays Market Forecast: AGR (%), 2016-2026 Figure 4.9 EU Market Breakdown by Nation: EU Market Shares (%), 2015 Figure 4.10 EU Market Breakdown by Nation: Revenues ($m), Market Shares (%), 2020 Figure 4.11 EU Market Breakdown by Nation: Revenues ($m), Market Shares (%), 2026 Figure 4.12 EU Market, Top National Forecasts: Revenue ($m), 2016-2026 Figure 4.13 German Cell-Based Assays Market Forecast: Revenues ($m), 2016-2026 Figure 4.14 German Cell-Based Assays Market Forecast: AGR (%), 2016-2026 Figure 4.15 French Cell-Based Assays Market Forecast: Revenues ($m), 2016-2026 Figure 4.16 French Cell-Based Assays Market Forecast: AGR (%), 2016-2026 Figure 4.17 UK Cell-Based Assays Market Forecast: Revenues ($m), 2016-2026 Figure 4.18 UK Cell-Based Assays Market Forecast: AGR (%), 2016-2026 Figure 4.19 Spanish Cell-Based Assays Market Forecast: AGR (%), 2016-2026 Figure 4.20 Spanish Cell-Based Assays Market Forecast: AGR (%), 2016-2026 Figure 4.21 Italian Cell-Based Assays Market Forecast: AGR (%), 2016-2026 Figure 4.22 Italian Cell-Based Assays Market Forecast: AGR (%), 2016-2026 Figure 4.23 Japanese Cell-Based Assays Market Forecast: AGR (%), 2016-2026 Figure 4.24 Japanese Cell-Based Assays Market Forecast: AGR (%), 2016-2026 Figure 4.25 BRIC Countries Breakdown by Nation: Market Shares (%), 2015 Figure 4.26 BRIC Countries Breakdown by Nation: Market Shares (%), 2020 Figure 4.27 BRIC Countries Breakdown by Nation: Market Shares (%), 2026 Figure 4.28 BRIC Countries Breakdown by Nation: Revenues ($m), 2016-2026 Figure 4.29 Chinese Cell-Based Assays Market Forecast: AGR (%), 2016-2026 Figure 4.30 Chinese Cell-Based Assays Market Forecast: AGR (%), 2016-2026 Figure 4.31 Indian Cell-Based Assays Market Forecast: Revenue ($m), 2016-2026 Figure 4.32 Indian Cell-Based Assays Market Forecast: AGR (%), 2016-2026 Figure 4.33 Russian Cell-Based Assays Market Forecast: Revenue ($m), 2016-2026 Figure 4.34 Russian Cell-Based Assays Market Forecast: AGR (%), 2016-2026 Figure 4.35 Brazilian Cell-Based Assays Market Forecast: Revenue ($m), 2016-2026 Figure 4.36 Brazilian Cell-Based Assays Market Forecast: AGR (%), 2016-2026 Figure 5.1 ThermoFisher Scientific Historical Sales: Revenue ($m), 2010-2015 Figure 5.2 PerkinElmer Revenue Breakdown: Revenue ($m) for Fiscal Year Ending 3rd January 2016 Figure 5.3 BD Revenue Breakdown: Revenue ($m), 2015 Figure 6.1 Charles River Laboratories Revenue Breakdown: Revenue ($m), 2013-2015 Figure 8.1 Strengths and Weaknesses of the Cell-Based Assay Market, 2016 Figure 8.2 Strengths and Weaknesses of the Cell-Based Assay Market, 2016 Figure 9.1 Projected growth from 2000-2025 with and without a solution for industrialisation of advanced 3D cell-based assays. Figure 9.2 Proportion of Types of Cell Based Assay Used n 2014 and Predicted in 2024 Figure 10.1 The Cell-Based Assay Submarket Revenue ($m) Breakdown by Products and Services, 2015, 2020 and 2026 Figure 10.2 The Cell-Based Assay Submarket Revenue ($m) Breakdown by Application: Drug Discovery, ADME and Basic Research, 2015, 2020 and 2026 Figure 10.3 Regional Breakdown of the Cell-Based Assay Market by Revenue ($m), 2015, 2020 and 2026
Affymetrix Alliance Regenerative Medicine AstraZeneca ATCC Axiogenesis Bayer BBC (British Broadcasting Corporation) BD (Becton, Dickinson and Company) Bio-Rad BioAgilytix BioCity Biocroi Biofocus BioSeek BioVision BMG Labtech CareFusion Corporation Cell Assay Innovations (CAI) Cellartis (Takara Bio) Cellomics Cellular Dynamics Charles River Laboratories Corning Covance CXR Biosciences Cyprotex Cytek CYTOO Di Carlo Laboratory DiscoveRx Dr. Reddy’s Laboratories ESI BIO (BioTime) European Lead Factory Eurostars Evotec Fisher Scientific Fluofarma ForteBio Foundation Top Institute Pharma GE Healthcare GenCell General Electric (GE) Harlan Laboratories Hubrecht Institute Imagen Biotech InSphero Janssen Japan Institute of Biomedical Research Jubilant Biosys Lead Discovery Centre GmbH Life Technologies Corporation Marin Biologic Laboratories Maxcyte Merck & Co. Molecular Devices Netherlands Cancer Institute OcellO Organovo PerkinElmer Pharmaceutical Product Development (PPD) Pharmacyclics PharmaTimes Princeton University Promega ProQinase QGel Quintiles ReNeuron ReproCELL Roche Sanofi Seahorse Bioscience SGS (Société Générale de Surveillance) Solvo SRU Biosystems Swiss Federal Institute of Technology SymCel Syncom The European Lead Factory (ELF) The Innovative Medicines Initiative (IMI) The National Health Service (NHS) The Netherlands Cancer Institute The Scientist Magazine Thermo Electron Thermo Fisher Scientific Trinity College, Dublin Tufts Center for the Study of Drug Development UCB (Union Chimique Belge) UCLA (University of California, Los Angeles) UK Department of Health University of Kyoto University of Oxford University of Zurich US Congress US FDA Vala Sciences WuXi
Download sample pages
Complete the form below to download your free sample pages for Cell-Based Assays World Industry and Market Prospects 2016-2026
Download sample pages
Complete the form below to download your free sample pages for Cell-Based Assays World Industry and Market Prospects 2016-2026
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
